Bromazolam

Concurrent opioid use without medical supervision is the primary mechanism in bromazolam-associated fatalities. Fentanyl was co-detected in 75–88% of postmortem bromazolam-positive cases. Naloxone reverses only the opioid component.

Bromazolam enhances inhibitory neurotransmission in brainstem respiratory centers via GABA-A potentiation, reducing respiratory drive. Patients with pre-existing respiratory insufficiency face compounded ventilatory compromise.

Benzodiazepine-class muscle relaxation via spinal interneuron and cerebellar GABAergic enhancement may exacerbate weakness in myasthenia gravis. Bromazolam's confirmed α2 subunit affinity (Ki = 0.69 nM) is consistent with myorelaxant effects.

Bromazolam demonstrated full dose-dependent substitution for midazolam in rat drug discrimination (ED50 = 0.54 mg/kg), confirming abuse potential comparable to scheduled benzodiazepines. Community reports document compulsive redosing facilitated by delusions of sobriety.

Bromazolam undergoes CYP3A4-dominant Phase I hydroxylation (Wagmann et al. 2021). Hepatic impairment reduces CYP3A4 activity, predictably elevating plasma concentrations and prolonging duration of effect. No bromazolam-specific hepatic impairment PK data exist.

Co-administration with CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, erythromycin, ritonavir, grapefruit juice) is expected to increase bromazolam plasma concentrations and prolong duration, paralleling the well-established alprazolam–CYP3A4 inhibitor interaction.

Patients with documented hypersensitivity to any benzodiazepine should avoid bromazolam due to shared triazolobenzodiazepine scaffold and potential cross-reactivity.

Benzodiazepines as a class carry teratogenicity risk and risk of neonatal withdrawal/floppy infant syndrome. No bromazolam-specific reproductive toxicity data exist.

Elderly patients demonstrate increased sensitivity to benzodiazepine CNS depression, reduced CYP3A4 metabolic capacity, and elevated risk of falls and fractures. No geriatric-specific bromazolam PK or safety data exist.

Standard benzodiazepine class contraindication for acute narrow-angle glaucoma. No bromazolam-specific ophthalmological data exist.